Tovet® Kit & Tovet® Foam

Helps reduce the itch and inflammation that present in hair-bearing areas or over large areas, including:

• Psoriasis
• Atopic dermatitis

Emollient Foam Vehicle:

• Elegant and non-greasy
• Spreads smoothly and easily to the site of inflammation
• Softens and soothes dry and irritated skin

Tovet^® Kit includes Keradan^® Cream

• Ceramide-rich cosmetic formulation minimizes moisture loss to soothe and soften irritated skin
• Elegant, non-greasy and fragrance-free formulation developed and tested by Dermatologists
• Helps optimize the skin’s pH

IMPORTANT PRODUCT INFORMATION - Tovet^® Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. 

Tovet^® Foam should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face or groin, axillae, or other intertriginous areas. If irritation develops, Tovet^® Foam should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids.

The most common adverse reactions (incidence ≥ 1%) are application site atrophy and application site reaction. Clobetasol propionate foam, 0.05% (emulsion) has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Systemic absorption of clobetasol propionate foam, 0.05% (emulsion) has caused reversible HPA axis suppression with the potential for clinical glucocorticoid insufficiency. Use of topical corticosteroids, including Tovet^® Foam, may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported postmarketing with the use of topical corticosteroids, including topical clobetasol products.